A method for constructing a colonic organoid model of diarrhea-predominant irritable bowel syndrome in mice and its application in evaluating intestinal barrier repair.

By constructing an IBS-D mouse colon organoid model, the problem of insufficient disease relevance in in vitro models in existing technologies has been solved, enabling effective evaluation of intestinal barrier repair drugs, which is applicable to the research of traditional Chinese medicine compound and natural products.

CN123107909APending Publication Date: 2026-11-17YANTAI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611563252.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-10
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing in vitro intestinal barrier models are insufficient to accurately reflect the chronic low-grade inflammation and barrier damage state of diarrhea-predominant irritable bowel syndrome (IBS-D), and there is a lack of stable passaged models suitable for evaluating drugs that repair the intestinal barrier.

Method used

Colonic organoids were constructed directly from the colonic crypts of IBS-D model mice, without the need for exogenous cytokine induction, preserving the IBS-D disease imprint. Furthermore, by constructing an intestinal barrier repair drug evaluation method, it is applicable to the evaluation of traditional Chinese medicine compound preparations and natural products.

Benefits of technology

A stable passage model of IBS-D mouse colonic organoids was established. Evaluation indicators included stemness and cellular composition, barrier integrity, balance of proliferation and apoptosis, and inflammation level, which were consistent with the pathological state of IBS-D mice. This model is suitable for screening and evaluating the intestinal barrier repair effects of traditional Chinese medicine compound and natural products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107909A_ABST
    Figure CN123107909A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biomedical technology and discloses a method for constructing a mouse colon organoid model of diarrhea-predominant irritable bowel syndrome (IBS-D) and its application in evaluating intestinal barrier repair. The mouse model is constructed using a combination of a warm and humid environment, chronic restraint, water avoidance, and chronic unpredictable mild stress. Mouse colons are harvested, digested, filtered, centrifuged, and then mixed with Matrigel for inoculation, cultured, and passaged. The model is identified by markers such as budding rate and goblet cells and enteroendocrine cells, and compared in parallel with Caco-2 cell models and disease-related mouse models. This model does not require exogenous cytokine induction and retains characteristics of chronic low-grade inflammation and barrier damage. Using Ge Gen Qin Lian Tang and baicalein as candidate drugs, indicators such as tight junction proteins, proliferation, and apoptosis are detected. Alternatively, transmembrane resistance and fluorescein-labeled dextran permeability are detected after the organoids are digested and cultured into a monolayer of cells. This invention provides an in vitro research model closely resembling the disease state for evaluating the intestinal barrier repair effects of traditional Chinese medicine compound formulas and natural products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a mouse colonic organoid model of diarrhea-predominant irritable bowel syndrome (IBS-D), and a method for evaluating drugs for intestinal barrier repair based on this model. This invention also relates to the application of this model in screening or evaluating drugs, traditional Chinese medicine formulas, or natural products with intestinal barrier repair effects. Background Technology

[0002] Irritable bowel syndrome (IBS) is a common functional bowel disorder characterized by recurrent abdominal pain, bloating, and changes in bowel habits, with a global prevalence of approximately 5%–10%. Diarrhea-predominant IBS-D is the most common subtype clinically, and its prevalence is also relatively high in the general population of my country. IBS-D severely impacts patients' quality of life and imposes a significant socioeconomic burden. Its pathogenesis is not fully understood, but it is currently believed to be related to multiple factors, including abnormal intestinal motility, visceral hypersensitivity, low-grade intestinal mucosal inflammation, intestinal microecological imbalance, and brain-gut axis dysfunction. Among these, impaired intestinal barrier function is considered a key pathological link in the development of IBS-D. The intestinal barrier is composed of intestinal epithelial cells and their tight junction proteins, mucus layer, and mucosal immune cells. Impairment of its integrity can lead to increased intestinal permeability, thereby inducing or aggravating symptoms such as abdominal pain and diarrhea. Therefore, repairing the intestinal barrier has become an important research direction in the evaluation of IBS-D drugs.

[0003] Currently, in vitro evaluation of intestinal barrier function mainly relies on the Caco-2 monolayer cell model, a human colon adenocarcinoma cell line. This model is widely used for measuring transmembrane electrical resistance and FITC-D permeability due to its simplicity and reproducibility. However, Caco-2 cells originate from colon adenocarcinoma and cannot systematically demonstrate the chronic low-grade inflammatory microenvironment and mucus layer / immune cell interactions unique to IBS-D, thus failing to accurately reflect the repair effects of drugs on the intestinal barrier under pathological conditions. Furthermore, Caco-2 inflammation models induced by exogenous stimuli such as lipopolysaccharide (LPS) typically exhibit a strong acute inflammatory response, which differs significantly from the pathological characteristics of chronic low-grade inflammation in IBS-D.

[0004] In recent years, the rise of organoid technology has provided new ideas for constructing in vitro disease models. Organoids are miniature organ-like structures formed by the self-assembly of pluripotent stem cells or adult stem cells under three-dimensional culture conditions, capable of highly mimicking the cellular composition, spatial structure, and some physiological functions of the source tissue. Studies have shown that colonic organoids derived from patient or disease animal models exhibit unique advantages in intestinal disease research because they retain the inflammatory tone and epigenetic characteristics of the disease state. However, existing colonic organoid models are mostly derived from normal tissues or directed differentiation of pluripotent stem cells, or used to induce barrier damage models using exogenous cytokines such as interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and LPS. These models are not directly derived from IBS-D disease model animals and cannot fully preserve the disease imprint of IBS-D, such as chronic low-grade inflammation, barrier damage, and epithelial repair imbalance. Furthermore, existing colonic organoid models still have shortcomings in terms of construction efficiency, passage stability, and the systematic nature of intestinal barrier function evaluation indicators. There is still a lack of a colonic organoid model that can directly carry IBS-D disease characteristics, requires no exogenous induction, can be stably passaged, and is suitable for evaluating intestinal barrier repair drugs.

[0005] Traditional Chinese medicine (TCM) has accumulated rich clinical experience in the treatment of IBS-D. Ge Gen Qin Lian Tang, originating from the *Shang Han Lun* (Treatise on Cold Damage), is composed of four herbs: kudzu root, scutellaria root, coptis root, and prepared licorice root. It is widely used in modern clinical practice for diarrhea caused by damp-heat accumulation in the intestines. Modern pharmacological studies have shown that Ge Gen Qin Lian Tang can exert a therapeutic effect on intestinal barrier damage by inhibiting inflammatory signaling pathways, regulating immune cell balance, restoring tight junction protein expression, improving intestinal permeability, and regulating intestinal homeostasis. Baicalein, one of the main flavonoid active components in scutellaria root, possesses various pharmacological activities, including anti-inflammatory, antioxidant, and maintenance of intestinal epithelial barrier integrity. However, current research on the repair of the intestinal barrier in IBS-D using TCM compound formulas and natural products mainly relies on Caco-2 cell models or animal experiments, lacking an in vitro evaluation system based on organoid models derived from IBS-D disease.

[0006] In view of this, the present invention provides an IBS-D mouse colonic organoid model, its construction method, and its application in the evaluation of intestinal barrier repair drugs, to solve the problems of insufficient disease relevance of existing in vitro models, difficulty in accurately reflecting the chronic low-grade inflammation and barrier damage state of IBS-D, and unsystematic evaluation indicators. The present invention directly constructs colonic organoids from the colonic crypts of IBS-D model mice, without the need for exogenous cytokine induction, retains the IBS-D disease imprint, and can be stably passaged. Based on this, a method for evaluating intestinal barrier repair drugs based on this model is established, providing a research model that more closely reflects the disease state for the intestinal efficacy evaluation of traditional Chinese medicine compound formulas and natural products. Summary of the Invention

[0007] This invention proposes a method for constructing a colonic organoid model of diarrhea-predominant irritable bowel syndrome (IBS-D) in mice and its application in the evaluation of intestinal barrier repair drugs. This method constructs an IBS-D mouse model and uses its colonic crypts as the source to build colonic organoids, eliminating the need for exogenous cytokine induction and preserving the chronic low-grade inflammation and barrier damage characteristics of IBS-D. Furthermore, based on this model, an evaluation method for intestinal barrier repair drugs is established, addressing the problems of insufficient disease relevance and inability to accurately reflect the pathological state of IBS-D in existing in vitro models.

[0008] This invention mainly includes the following steps:

[0009] (1) Construction of IBS-D mouse model

[0010] An IBS-D mouse model was established using a combination of humid and hot environment with chronic restraint stress, water avoidance stress, and chronic unpredictable mild stress. During the modeling period, the ambient temperature was maintained at (28±2)℃ and the relative humidity at 90% for 8 weeks. Chronic restraint stress involved placing mice in 50 mL centrifuge tubes daily, with their tails fixed and the tube bottom slit for ventilation, for 2 hours. Water avoidance stress involved placing mice on an inverted water cup platform with the water level 1–2 cm below the bottom of the cup for 2 hours. Chronic unpredictable mild stress involved randomly selecting 1–2 stimuli daily, including 24 hours of water deprivation, 24 hours of fasting, 5 minutes of tail clamping, 12 hours of cage tilting at 45°, 36 hours of continuous light exposure, 12 hours of moist bedding, 5 minutes of hanging, and 45 minutes of horizontal shaking, for 2 consecutive days without repetition, with the same stimulus administered no more than 3 times per week. After modeling, compared with the control group, slower weight gain and increased Bristol fecal score, fecal pellet number, fecal water content, and abdominal withdrawal reflex score confirmed the successful establishment of the model.

[0011] (2) Separation of the colonic recess

[0012] IBS-D mice and normal control mice were euthanized by cervical dislocation, and colonic segments were harvested. Adipose tissue was removed, and the colon was longitudinally dissected along the mesentery. The colon was repeatedly rinsed with pre-cooled DPBS. The colonic segments were cut into 2–3 mm pieces and placed in DPBS containing 5 mmol / L EDTA. Digestion was performed at 4°C for 30 min, and the crypts were gently detached by pipetting. The crypts were filtered through a 70 μm cell sieve and centrifuged at 4°C, 200 × g for 5 min. The supernatant was discarded. The precipitate was resuspended in DPBS, and the number of crypts was counted.

[0013] (3) Culture and passage of colon organoids

[0014] Mix crypts with matrix gel at a 1:1 ratio, and seed approximately 300 crypts per well into a 24-well plate (35 μL per well). Incubate at 37°C for 30 min to allow the matrix gel to solidify. Add 500 μL of preheated colon organoid complete culture medium per well. Change the culture medium every 2–3 days and culture for 7 days. Subculture the organoids every 5–7 days at a 1:2 ratio.

[0015] (4) Identification of IBS-D colon organoid model

[0016] The stemness of organoids was characterized by budding rate statistics. Budding was defined as a raised structure with a diameter ≥10 μm at the edge of the organoid spheroid. The budding rate = number of buds / total number of organoids × 100%. Immunofluorescence staining was used to detect markers such as MUC2, ChgA, ALPI, LyzM, and STAB2 to identify the cellular composition and epithelial properties of organoids. IBS-D colonic organoids should have colonic markers, namely, one or more of the following: MUC2 expression, ChgA expression, ALPI expression, and STAB2 expression, and should not contain LyzM expression.

[0017] (5) Evaluation of drugs for intestinal barrier repair based on IBS-D colon organoids

[0018] IBS-D mouse colonic organoids were digested into single cells and seeded into Transwell chambers coated with 20% Substrate gel. Transmembrane resistance was measured daily during culture until a stable IBS-D colonic organoid-derived epithelial monolayer with stable transmembrane resistance was formed. The candidate drug was then applied to the IBS-D colonic organoids, and one or more of the following parameters were measured: budding rate, ZO-1 expression, proportion of EdU-positive cells, proportion of TUNEL-positive cells, and levels of TNF-α and IL-6. The candidate drug was then applied to the organoid-derived epithelial monolayer, and transmembrane resistance and FITC-D permeability were measured. If the candidate drug treatment resulted in increased budding rate, enhanced ZO-1 expression, increased proportion of EdU-positive cells, decreased proportion of TUNEL-positive cells, and / or decreased levels of TNF-α and IL-6, the candidate drug was deemed to have intestinal barrier repair activity. If the candidate drug treatment resulted in increased transmembrane resistance and decreased relative fluorescence intensity of FITC-D, the candidate drug was deemed to have intestinal barrier repair activity. Simultaneously, it was compared in parallel with the LPS-induced Caco-2 cell model and validated in vivo using the IBS-D mouse model. Colon pathology was observed by H&E staining, intestinal permeability was evaluated by FITC-D intestinal permeability assay, and TNF-α and IL-6 levels in colon tissue were detected by ELISA.

[0019] (6) Evaluation of intestinal barrier repair by Ge Gen Qin Lian Tang

[0020] Ge Gen Qin Lian Tang extract was used to intervene in IBS-D colonic organoids at concentrations of 50, 100, and 200 μg / mL, and budding rate, ZO-1, TNF-α, and IL-6 were detected. The results showed that Ge Gen Qin Lian Tang could dose-dependently increase budding rate and ZO-1 expression, and decrease TNF-α and IL-6 levels, consistent with the trends observed in IBS-D mice.

[0021] (7) Evaluation of baicalin intestinal barrier repair

[0022] Baicalein was used to intervene in IBS-D colonic organoids or organoid-derived epithelial monolayers at doses of 5, 10, 20, 40, and 80 μM. The budding rate of colonic organoids, the proportion of EdU-positive cells, and the proportion of TUNEL-positive cells were measured. The transmembrane resistance and FITC-D relative fluorescence intensity of the organoid-derived epithelial monolayers were also measured. The results showed that baicalein could promote epithelial proliferation, inhibit apoptosis, and restore barrier function in a dose-dependent manner.

[0023] This invention directly constructs colonic organoids from the colonic crypts of IBS-D model mice, without the need for exogenous cytokine induction, and retains the characteristics of chronic low-grade inflammation and barrier damage in IBS-D mice. The evaluation indicators cover stemness and cell composition, barrier integrity, proliferation and apoptosis balance, and inflammation level, which are consistent with the pathological state in IBS-D mice. It is suitable for screening and evaluating the intestinal barrier repair effects of traditional Chinese medicine compound and natural products. Attached Figure Description

[0024] Figure 1 This is a flowchart illustrating the construction of an IBS-D mouse colon organoid model and the evaluation of drugs for intestinal barrier repair.

[0025] Figure 2 The images show the morphological characteristics of colonic organoids constructed and passaged from IBS-D mice. (A) shows the organoid morphology 1–8 days after construction, and (B) shows the organoid morphology 1–4 days after passage.

[0026] Figure 3 The staining pattern for identifying colonic organoids in IBS-D mice includes markers such as goblet cell marker MUC2, enteroendocrine cell marker ChgA, microfolded cell marker STAB2, absorptive intestinal epithelial marker ALPI, and Paneth cell marker LyzM.

[0027] Figure 4 The effect of Gegen Qinlian Decoction on the function of Caco-2 monolayer cell barrier (control model) is shown in the figure. (A) represents cell viability, (B) represents transmembrane resistance, (C) represents the FITC-D standard curve, and (D) represents serum FITC-D concentration. Compared with the CON group, ## P<0.01, ###P<0.001; compared with the MOL group, *P<0.05, **P<0.01, ***P<0.001.

[0028] Figure 5 The effect of Gegen Qinlian Decoction on Calcein-AM / PI live / dead staining of IBS-D colonic organoids was investigated. Compared with the Health group, ## P<0.01, ### P<0.001; compared with the IBS-D group, *P<0.05, **P<0.01, ***P<0.001.

[0029] Figure 6 The effects of Ge Gen Qin Lian Tang on the morphology and germination rate of colonic organoids in IBS-D were shown in Figure (A), which is a bright-field morphology graph, and Figure (B) is a germination rate statistical graph. Compared with the Health group, ### P<0.001; compared with the IBS-D group, *P<0.05, **P<0.01.

[0030] Figure 7 The effect of Gegen Qinlian Decoction on ZO-1 expression in IBS-D colonic organoids was investigated. (A) shows the immunofluorescence staining pattern of ZO-1, and (B) shows the statistical graph of relative fluorescence intensity of ZO-1. Compared with the Health group, ## P<0.01; compared with the IBS-D group, *P<0.05.

[0031] Figure 8 This image shows a comparative analysis of inflammatory factor levels in IBS-D colonic organoids, Caco-2 cells, and IBS-D mouse colonic tissue. (A) represents TNF-α levels, and (B) represents IL-6 levels. Compared to the CON group or the Health group, ## P<0.01, ### P<0.001; compared with the MOL group or the IBS-D group, *P<0.05, **P<0.01, ***P<0.001.

[0032] Figure 9 This study investigated the effects of Ge Gen Qin Lian Tang on core symptoms, intestinal permeability, and colonic pathology in IBS-D mice (control model). (A) represents body weight, (B) represents the Bristol fecal score, (C) represents the number of fecal particles, (D) represents fecal water content, (E) represents the abdominal wall withdrawal reflex score, (F) represents the serum FITC-D standard curve, (G) represents the serum FITC-D concentration, (H) represents the colonic H&E staining image, and (I) represents the histopathological score. Black arrows indicate abnormal crypt morphology, blue arrows indicate inflammatory cell infiltration, red arrows indicate muscle layer edema, and purple arrows indicate epithelial cell shedding. Compared with the CON group, [the results were not specified in the original text]. ##P<0.01, ### P<0.001; compared with the MOL group, *P<0.05, **P<0.01, ***P<0.001.

[0033] Figure 10 The image shows the effect of baicalin on the organoid barrier function of the colon in IBS-D mice. (A) is a bright-field morphology diagram of the organoids; (B) is a budding rate statistical graph; (C) is a schematic diagram of organoids digested into single cells and seeded into Transwell chambers; (D) is the transmembrane resistance of the organoid-derived epithelial monolayer; and (E) is the FITC-D content of the organoid-derived epithelial monolayer. Compared with the Health group, ## P<0.01; compared with the IBS-D group, *P<0.05, **P<0.01.

[0034] Figure 11 The effects of baicalin on the proliferation and apoptosis of colonic organoids in IBS-D mice are shown in Figures (A, B, C, and D). (A) shows the EdU immunofluorescence staining pattern, (B) shows the percentage of EdU-positive cells, (C) shows the TUNEL immunofluorescence staining pattern, and (D) shows the percentage of TUNEL-positive cells. Compared with the Health group, ## P<0.01; compared with the IBS-D group, *P<0.05, **P<0.01. Detailed Implementation

[0035] Example 1

[0036] Construction, passage and identification of colonic organoids from IBS-D mice

[0037] (1) Construction of IBS-D mouse model

[0038] SPF-grade male C57BL / 6 mice, 6 weeks old, weighing 18–20 g, were housed in an SPF-grade animal facility at a temperature of 24±1℃ and a relative humidity of 50%–60%, with a 12-hour light-dark cycle and free access to food and water. All animal experiments were approved by the animal ethics committee. An IBS-D mouse model was established using a combination of humid heat environment, chronic restraint stress, water avoidance stress, and chronic unpredictable mild stress. During the modeling period, the ambient temperature was maintained at (28±2)℃ and the relative humidity at 90% daily for 8 weeks. Chronic restraint stress: Mice were placed in 50 mL centrifuge tubes daily, with their tails secured with a glove plug and the tube bottom slit kept ventilated, for 2 hours. Water avoidance stress: Mice were placed on an inverted water cup (3 cm radius) platform, which was placed in a water tank with the water level 1–2 cm below the bottom of the cup, for 2 hours. Chronic, unpredictable, mild stress included: 24-hour water deprivation, 24-hour fasting, 5-minute tail clamping, 12-hour cage tilt at 45°, 36-hour continuous light exposure, 12-hour moist bedding, 5-minute hanging, and 45-minute horizontal shaking. One to two stimuli were randomly selected daily for two consecutive days without repetition, and the same stimulus was used no more than three times per week. After model establishment, body weight, Bristol fecal score, number of fecal pellets, fecal water content, and abdominal withdrawal reflex score were used as indicators for IBS-D model evaluation. The Bristol fecal score was rated from 1 to 7, with a higher score indicating that the feces were closer to watery stool. Fecal water content = (wet weight - dry weight) / wet weight × 100%. For the abdominal withdrawal reflex test, mice were fasted for 16 hours and then anesthetized with isoflurane. A lubricated balloon was inserted through the anus, followed by a 30-second adaptation period. The balloon was then inflated sequentially to 0.1, 0.2, and 0.3 mL using a syringe, each inflation lasting 20 seconds with a 5-minute interval. Two observers scored the mice blinded from 0 to 4. Measurements were taken three times for each inflation volume, and the average value was recorded. Mice with successful modeling were randomly divided into a model group and low, medium, and high dose GQD groups, with a normal control group (n=6). For 8 consecutive weeks, mice were administered Ge Gen Qin Lian Tang extract (low / medium / high concentrations of 2, 4, and 8 g / kg, respectively, based on crude drug weight) by gavage. The normal and model groups received the same volume of solvent.

[0039] (2) Isolation of colonic crypts, inoculation and culture of colonic organoids

[0040] IBS-D mice with successful modeling and normal control (Health group) mice were euthanized by cervical dislocation, and colonic segments were harvested. Attached adipose tissue was removed, and the colon was longitudinally dissected along the mesentery. The colonic segments were repeatedly rinsed with pre-cooled DPBS until all contents were removed. The colonic segments were cut into 2–3 mm pieces and placed in DPBS containing 5 mmol / L EDTA. Digestion was performed at 4°C for 30 min, and the crypts were gently detached by pipetting. The filtrate was filtered through a 70 μm cell sieve, collected, and centrifuged at 200×g for 5 min at 4°C. The supernatant was discarded. The precipitate was resuspended in DPBS, and the number of crypts was counted. The crypts were mixed with matrix gel at a 1:1 ratio and seeded into 24-well plates at a density of approximately 300 crypts per well (35 μL per well). The plates were incubated at 37°C for 30 min to allow the matrix gel to solidify. Preheated colonic organoid complete culture medium was added (500 μL per well). The culture medium was changed every 2–3 days, and subsequent experiments were performed after 7 days of culture.

[0041] (3) Organoid passage and morphological observation

[0042] Organoids were passaged every 5–7 days. The culture medium was discarded, pre-cooled DPBS was added, and the matrix gel and organoids were gently resuspended by pipetting. The cells were centrifuged at 200×g for 5 min at 4°C, and the supernatant was discarded. Organoid dissociation buffer was added, or the organoids were dispersed into small cell clusters by mechanical pipetting. The cells were resuspended in fresh matrix gel at a 1:2 ratio and seeded into 24-well plates (35 μL per well). The plates were incubated at 37°C for 30 min to allow the matrix gel to solidify. Preheated colon organoid complete culture medium (500 μL per well) was added, and the cells were cultured further. Bright-field images were acquired using an inverted fluorescence microscope. Morphological changes in the organoids were observed 1–8 days after construction, and post-passage morphological changes were observed 1–4 days after passage. Results are as follows: Figure 2 As shown, after construction, the organoids gradually formed sac-like structures and exhibited budding; after passage, the organoids could reform typical crypt-like structures. Compared with normal mouse colon organoids, IBS-D mouse colon organoids showed reduced budding structures, thickened sac walls, and a decreased budding rate, suggesting impaired stemness and retention of IBS-D disease characteristics.

[0043] (4) Identification of organoid markers

[0044] Organoids were identified using whole-body immunofluorescence staining. Organoids were recovered from matrix gel, fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.5% Triton X-100 for 20 min, blocked with 5% bovine serum albumin for 2 h, and then incubated overnight at 4°C with primary antibodies against MUC2, ChgA, STAB2, ALPI, and LyzM, respectively. After washing, secondary antibody labeled with Alexa Fluor 594 was added, and the mixture was incubated at room temperature in the dark for 2 h, followed by DAPI staining of the nuclei. Z-stack scanning of the intermediate layer of the organoids was performed under a laser confocal microscope to acquire images.

[0045] The results are as follows Figure 3 As shown, MUC2-positive goblet cells, ChgA-positive enteroendocrine cells, STAB2-positive microfolded cells, and ALPI-positive absorptive intestinal epithelial cells were all detected in the colonic organoids of IBS-D mice, indicating that the constructed organoids retained the multicellular composition and epithelial polarity structure of the colonic epithelium. Since the colon does not contain Paneth cells, LyzM positivity could not be detected. Combining the budding rate and morphological results, the successful construction of the IBS-D mouse colonic organoid model is demonstrated. This model can be stably passaged and retains the IBS-D disease imprint, and can be used for subsequent evaluation of intestinal barrier repair drugs.

[0046] Example 2

[0047] Evaluation of the effect of Gegen Qinlian Decoction on the intestinal barrier repair of colonic organoids in IBS-D

[0048] (1) Preparation of Gegen Qinlian Decoction Extract

[0049] Take kudzu root, scutellaria root, coptis root, and prepared licorice root slices, pulverize them, and pass them through a 40-mesh sieve. Weigh them in a mass ratio of 5:3:3:2. Place 250 g of kudzu root powder in a clay pot, add 2 L of ultrapure water and soak for 0.5 h. First, bring to a boil over high heat, then simmer over low heat for 0.5 h. Then, add the remaining medicinal materials in the same proportion and heat together for 1 h. After the extract cools to room temperature, centrifuge at 3500×g for 10 min at 4℃ and collect the supernatant. Concentrate the supernatant under reduced pressure at 50℃ to an appropriate volume, and then freeze-dry (-40℃, 48 h) to obtain the Kudzu Root, Scutellaria Root, and Coptis Root Decoction Extract (GQD), which is stored at -20℃ for later use. Analysis by UHPLC-Q-TOF-MS revealed that GQD mainly contains flavonoids (such as puerarin, daidzein, baicalin, wogonin, baicalin, etc.), alkaloids (such as berberine, epiberberine, baicalein, etc.), organic acids (such as chlorogenic acid, caffeic acid, etc.) and triterpenoids (such as glycyrrhizic acid, glycyrrhetinic acid, etc.).

[0050] (2) Effects of Gegen Qinlian Decoction on the function of Caco-2 monolayer cell barrier (control model)

[0051] Caco-2 cells were routinely passaged in DMEM high-glucose medium containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C in a 5% CO2 incubator. Logarithmic growth phase Caco-2 cells were then cultured at a concentration of 1×10⁻⁶ cells / cells. 4 Cells were seeded per well in 96-well plates and cultured for 24 h until adherence. Cells were then treated with 12.5, 25, 50, 100, 200, 400, and 800 μg / mL GQD for 24 h, respectively, with a blank control group (CON). All other treatment conditions were the same. Cell viability was assessed using the MTT assay. Results are shown below. Figure 4As shown in Figure A, GQD showed no significant cytotoxicity to Caco-2 cells within the concentration range of 0–200 μg / mL, and the cell survival rate was greater than 90%. Therefore, 50, 100, and 200 μg / mL were selected as subsequent drug administration concentrations.

[0052] Caco-2 cells were fed at a rate of 2.6 × 10⁻⁶. 5 pcs / cm 2 The cells were seeded at a density on Transwell nests and cultured for 21 days to form a differentiated monolayer with a transmembrane resistivity >500 Ω·cm. 2 Only after these conditions were met could subsequent experiments be conducted. The experiment was divided into a blank control group (CON), a model group (MOL, 1 μg / mL LPS stimulation), and low / medium / high concentration GQD groups (50, 100, 200 μg / mL). Except for the blank group, the other groups were first stimulated with 1 μg / mL LPS for 24 h, then gently washed with PBS, and then incubated for another 24 h with low / medium / high concentrations of GQD. After drug intervention, EVOM was used... 2 The measuring instrument measures the transmembrane resistance, and the results are expressed in Ω·cm. 2 The results are as follows. Simultaneously, a standard curve was prepared by dissolving FITC-D (4 kDa) in HBSS, and the FITC-D concentration was determined by sampling in the lower chamber of a Transwell apparatus. Figure 4 As shown in B-D, after LPS stimulation, the transmembrane resistance of Caco-2 monolayer cells decreased and the FITC-D concentration increased, indicating impaired barrier function; after GQD intervention, the transmembrane resistance increased in a dose-dependent manner and the FITC-D concentration decreased in a dose-dependent manner.

[0053] (3) Determination of the effect of Ge Gen Qin Lian Tang on Calcein-AM / PI live and dead staining of IBS-D colonic organoids and determination of drug concentration

[0054] Colonic organoids from IBS-D mice cultured for 7 days were treated with GQD at concentrations of 25, 50, 100, 200, and 400 μg / mL for 24 h. Live and dead cell staining was performed using the Calcein-AM / PI double staining method: organoids were recovered, washed twice with DPBS, and incubated at 37°C for 30 min in the dark with staining working solution containing 2 μmol / L Calcein-AM and 4 μmol / L PI. After washing with DPBS, images were acquired under a laser confocal microscope; green fluorescence indicated live cells, and red fluorescence indicated dead cells. Cell viability was calculated. Results are as follows: Figure 5As shown, within the concentration range of 25–200 μg / mL, the proportion of viable cells in IBS-D colonic organoids increased in a dose-dependent manner after GQD intervention; when the concentration increased to 400 μg / mL, the proportion of viable cells decreased slightly compared to 200 μg / mL, suggesting that high concentrations of GQD may produce certain cytotoxicity. Subsequent organoid pharmacodynamic experiments used 50, 100, and 200 μg / mL as the administration concentrations.

[0055] (4) Effects of Gegen Qinlian Decoction on the morphology and budding rate of colonic organoids in IBS-D

[0056] Colonic organoids from IBS-D mice cultured for 7 days were added to complete culture medium containing different concentrations of GQD (25, 50, 100, 200, 400 μg / mL) for 24 h. Colonic organoids from normal mice were added to complete culture medium containing an equal volume of DMSO. Bright-field images were acquired under an inverted fluorescence microscope. Twenty organoids were randomly selected from each group, and the organoid diameter and number of buds were measured using ImageJ software. Buds were defined as protruding structures with a diameter ≥10 μm at the edge of the organoid spheroid, and the budding rate was calculated as (number of buds / total number of organoids) × 100%. Each experiment was independently repeated three times.

[0057] The results are as follows Figure 6 As shown in Figure A, normal mouse colonic organoids exhibit a complex three-dimensional configuration with abundant budding structures, thin and translucent capsule walls, and branching edges. In IBS-D mouse colonic organoids, budding structures are significantly reduced or even absent, and the capsule walls are markedly thickened. After GQD intervention, the complex three-dimensional configuration of IBS-D organoids is reconstructed, the walls become thinner, and the number of buds increases. The budding rate statistics are shown below. Figure 6 As shown in B, the budding rate of IBS-D organoids was significantly lower than that of normal organoids; the budding rate of all GQD treatment groups was higher than that of the IBS-D group, and increased in a dose-dependent manner within the range of 50–200 μg / mL.

[0058] (5) Effect of Gegen Qinlian Decoction on ZO-1 expression in IBS-D colonic organoids

[0059] Colonic organoids from each group were collected 24 h after GQD intervention and stained with whole immunofluorescence. The organoids were recovered from Matrigel, fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.5% Triton X-100 for 20 min, blocked with 5% bovine serum albumin for 2 h, and incubated overnight at 4°C with rabbit anti-ZO-1 antibody (1:200). After washing, they were incubated for 2 h at room temperature in the dark with Alexa Fluor 594-labeled goat anti-rabbit secondary antibody (1:500), followed by DAPI staining of the nuclei. Z-stack scanning of the intermediate layer of the organoids was performed under a laser confocal microscope, and images were acquired. Semi-quantitative analysis of ZO-1 fluorescence intensity was performed using ImageJ software.

[0060] The results are as follows Figure 7 As shown in A-B, normal organoid ZO-1 is distributed in a continuous ring on the cell membrane with high fluorescence intensity; the fluorescence intensity of IBS-D organoid ZO-1 is significantly reduced and the distribution is discontinuous, indicating barrier damage; after GQD intervention, the fluorescence intensity of ZO-1 increased in a dose-dependent manner, and the 100 and 200 μg / mL concentration groups were significantly different from the IBS-D group.

[0061] (6) Comparative analysis of inflammatory factor levels in different models

[0062] To further compare the differences in inflammatory response intensity among three models—Caco-2 cells, IBS-D colonic organoids, and IBS-D mouse colonic tissue—Caco-2 cell supernatant, IBS-D organoid supernatant, and mouse colonic tissue homogenate were collected, and TNF-α and IL-6 levels were detected using ELISA. Results are as follows: Figure 8 As shown in A-B, in all three models, the levels of TNF-α and IL-6 in the model group were higher than those in the normal group; the levels of inflammatory factors decreased after GQD intervention in a dose-dependent manner. The levels of TNF-α and IL-6 in LPS-stimulated Caco-2 cells were significantly higher than those in IBS-D organoids; while the levels of inflammatory factors in IBS-D organoids were closer to those in IBS-D mouse colon tissue homogenate, both showing a relatively mild increase. These results suggest that the LPS-induced Caco-2 model exhibits a strong acute inflammatory response, while the inflammatory level of IBS-D organoids more closely resembles the chronic low-grade inflammatory state of IBS-D in vivo.

[0063] (7) Effects of Gegen Qinlian Decoction on core symptoms, intestinal permeability and colonic pathology in IBS-D mice (in vivo verification)

[0064] IBS-D mice that had successfully developed the model were randomly divided into four groups: a model group (MOL), a low-dose Gegen Qinlian Decoction group (GQDL), a medium-dose group (GQDM), and a high-dose group (GQDH). A normal control group (CON) was also included. All groups received the medication via gavage daily for 8 weeks. Body weight was recorded every 48 hours during the treatment period. Fresh feces were collected within 1 hour after the last administration, scored according to the Bristol fecal scoring system, and the number of fecal pellets was recorded. The wet weight of the feces was weighed and dried at 50℃ for 12 hours, and the fecal water content was calculated. The abdominal wall withdrawal reflex score was measured using the colonic dilatation method. Intestinal permeability was then tested. Mice were fasted for 12 hours (with free access to water) and then administered FITC-D solution by gavage at a dose of 600 mg / kg. During this period, the mice were kept in the dark and without food, but with free access to water. Blood was collected 4 hours later, and serum was separated by centrifugation at 3000×g for 15 min at 4℃. The FITC-D standard was serially diluted with PBS, and the fluorescence intensity was measured using a fluorescence microplate reader (excitation wavelength 485 nm, emission wavelength 525 nm) to plot a standard curve. The serum samples were measured in the same way, and the serum FITC-D concentration was calculated based on the standard curve.

[0065] Colonic tissue was collected, fixed in 4% paraformaldehyde for 24 h, dehydrated with graded ethanol, embedded in paraffin, and sectioned at a thickness of 4 μm. Sections were dewaxed to water, stained with hematoxylin for 5 min, differentiated with hydrochloric acid and ethanol, stained with eosin for 3 min, dehydrated and cleared, and mounted. The morphology of the colonic mucosa, crypt structure, inflammatory cell infiltration, and mucosal damage were observed under an optical microscope, and histopathological scoring was performed.

[0066] The results are as follows Figure 9 As shown in the figure. Compared with the CON group, the MOL group mice showed slower weight gain, increased Bristol fecal score, increased fecal pellet number, increased fecal water content, and increased abdominal wall withdrawal reflex score; the above indicators improved in a dose-dependent manner in each GQD dose group, with the high-dose group showing the most significant effect. Compared with the CON group, the MOL group showed increased serum FITC-D concentration, colonic mucosal crypt structure destruction, epithelial cell shedding, and inflammatory cell infiltration, and an increased histopathological score; after GQD intervention, serum FITC-D concentration decreased, colonic mucosal damage was reduced, and the histopathological score decreased. The above in vivo validation results are consistent with the trends of the in vitro efficacy evaluation results of IBS-D colonic organoids, indicating that Ge Gen Qin Lian Tang has a repairing effect on the intestinal barrier of IBS-D mice, and this effect can be reflected in the IBS-D colonic organoid model.

[0067] Example 3

[0068] Evaluation of the effect of baicalin on the intestinal barrier repair of colonic organoids in IBS-D

[0069] (1) Effects of baicalin on organoid barrier function of colon in IBS-D

[0070] Colonic organoids from IBS-D mice cultured for 7 days were treated with 0, 5, 10, 20, 40, and 80 μM baicalein, respectively. Bright-field images were acquired under an inverted fluorescence microscope. Twenty organoids were randomly selected from each group, and the budding rate was calculated. Budding was defined as a protruding structure with a diameter ≥10 μm at the edge of the organoid spheroid. The budding rate = number of buds / total number of organoids × 100%.

[0071] IBS-D mouse colonic organoids were digested into single cells and seeded into Transwell chambers coated with 20% Substrate gel. Transmembrane resistance was measured daily during culture until a stable IBS-D colonic organoid-derived epithelial monolayer with stable transmembrane resistance was formed. Transmembrane resistance was measured, and the relative fluorescence intensity of FITC-D in the lower chamber of the Transwell chamber was determined. Results are as follows: Figure 10 As shown, compared with normal colonic organoids, IBS-D colonic organoids exhibited decreased budding rate, decreased transmembrane resistance, and increased FITC-D content. After intervention with baicalein, the budding rate of IBS-D colonic organoids increased in a dose-dependent manner, with high transmembrane resistance and decreased FITC-D content, indicating that baicalein can restore the barrier function of IBS-D colonic organoids.

[0072] (2) Effects of baicalin on the proliferation and apoptosis of colonic organoids in IBS-D

[0073] IBS-D colonic organoids were treated with 10, 20, and 40 μM baicalein for 48 h. EdU staining was used to detect cell proliferation, and TUNEL staining was used to detect cell apoptosis. Z-stack images were acquired under a laser confocal microscope, and quantitative analysis was performed using maximum intensity projection. Results are as follows: Figure 11 As shown, compared with normal colonic organoids, the proportion of EdU-positive cells and the proportion of TUNEL-positive cells in IBS-D colonic organoids decreased, while the proportion of TUNEL-positive cells increased. After intervention with baicalin, the proportion of EdU-positive cells increased and the proportion of TUNEL-positive cells decreased, indicating that baicalin can promote epithelial proliferation and inhibit apoptosis in IBS-D colonic organoids, thereby restoring the epithelial proliferation-apoptosis balance.

Claims

1. A method of constructing a mouse colonic organoid model of diarrhea-predominant irritable bowel syndrome (IBS-D), characterized by, Includes the following steps: (1) An IBS-D mouse model was constructed by using a combination of hot and humid environment, chronic restraint stress, water avoidance stress, and chronic unpredictable mild stress for 8 weeks. (2) Collect colon tissue from IBS-D mice and separate the colonic crypts; (3) Mix the colonic crypts with matrix gel, inoculate, solidify, and then add colonic organoid complete culture medium for culture; (4) Transmission; (5) The success of the IBS-D mouse colon organoid model can be determined by budding rate and / or immunofluorescence staining.

2. The method of claim 1, wherein, In step (1), the ambient temperature was maintained at (28±2)℃ and the relative humidity at 90% during the modeling period. Chronic restraint stress involved placing mice in a 50 mL centrifuge tube, fixing their tails, and ventilating the bottom of the tube for 2 hours. Water avoidance stress involved placing mice on an inverted water cup platform with the water level 1-2 cm below the bottom of the cup for 2 hours. Chronic unpredictable mild stress included water deprivation for 24 hours, food deprivation for 24 hours, tail clamping for 5 minutes, tilting the cage at 45° for 12 hours, continuous light exposure for 36 hours, damp bedding for 12 hours, hanging for 5 minutes, and horizontal shaking for 45 minutes. One to two stimuli were randomly selected each day for two consecutive days without repetition, and the same stimulus was not repeated more than three times per week.

3. The method of claim 1, wherein, In step (2), the intestinal segment is cut into small pieces of 2-3 mm, placed in phosphate buffer (EDTA) containing 5 mmol / L EDTA, digested at 4°C for 30 min, filtered through a 70 μm cell sieve, centrifuged at 4°C and 200×g for 5 min, and the precipitate is resuspended in DuPont modified phosphate buffer (DPBS).

4. The method of claim 1, wherein, In step (3), the crypts and matrix gel are mixed in a 1:1 ratio and inoculated into a 24-well plate at a density of 200 to 400 crypts per well, 35 μL per well. The plate is incubated at 37°C for 30 min to allow the matrix gel to solidify. Preheated colon organoid complete culture medium is added, 500 μL per well. The culture medium is changed every 2 to 3 days.

5. The method of claim 1, wherein, In step (4), the organoids are passaged every 5 to 7 days. The culture medium is discarded, pre-cooled phosphate buffer is added, and the matrix gel and organoids are gently blown to recover them. After centrifugation, the supernatant is discarded, and organoid dissociation solution is added or the organoids are dispersed into small cell clusters by mechanical blowing. The organoids are resuspended in fresh matrix gel at a ratio of 1:2, inoculated, and after solidification, preheated colon organoid complete culture medium is added for continued culture.

6. The method of claim 1, wherein, In step (5), budding is defined as a raised structure with a diameter ≥10 μm at the edge of the organoid sphere, and the budding rate = number of buds / total number of organoids × 100%; the immunofluorescence staining markers include one or more of the following: goblet cell marker MUC2, enteroendocrine cell marker ChgA, microfolded cell marker STAB2, and absorptive intestinal epithelial marker ALPI, and do not contain Paneth cell marker LyzM.

7. An IBS-D mouse colon organoid model constructed by the method described in any one of claims 1 to 6.

8. The application of the IBS-D mouse colon organoid model of claim 7 in screening or evaluating intestinal barrier repair drugs.

9. Use according to claim 8, characterized in that, The drugs include traditional Chinese medicine compound formulas, natural products, chemical drugs, or biological agents.

10. A method for evaluating an intestinal barrier repair drug based on the IBS-D mouse colon organoid model according to claim 7, characterized by, Includes the following steps: (1) IBS-D mouse colon organoids were digested into single cells and seeded in Transwell chambers coated with 20% matrix gel. Transmembrane resistance was measured daily during culture until a monolayer of IBS-D colon organoid-derived epithelium with stable transmembrane resistance was formed. (2) The candidate drugs were used to intervene in organoids and organoid-derived epithelial monolayers, respectively; (3) Detect intestinal barrier repair-related indicators; (4) Determine whether the candidate drug has the function of intestinal barrier repair.

11. The method according to claim 10, characterized in that, The indicators described in step (3) include detecting organoid budding rate, tight junction protein (ZO-1) expression, proliferation level (EdU-positive cell proportion), apoptosis level (TUNEL-positive cell proportion), inflammatory factor levels (TNF-α level, IL-6 level), colonic markers (one or more of MUC2 expression, ChgA expression, ALPI expression, and STAB2 expression, but without LyzM expression), as well as detecting transmembrane resistance of organoid-derived epithelial monolayers and FITC-D permeability.

12. The method according to claim 10, characterized in that, In step (4), if the budding rate of organoids increases, tight junction protein expression is enhanced, proliferation level increases, apoptosis level decreases, and inflammatory factor level decreases after intervention with the candidate drug, then the candidate drug is determined to have an intestinal barrier repair effect. If the transmembrane resistance of the organoid-derived epithelial monolayer increases and FITC-D permeability decreases after intervention with the candidate drug, then the candidate drug is determined to have an intestinal barrier repair effect.

13. The method according to claim 10, characterized in that, The candidate drug is an extract of Ge Gen Qin Lian Tang, administered at a concentration of 50, 100, or 200 μg / mL.

14. The method according to claim 10, characterized in that, The candidate drug is baicalein, administered at one of the following concentrations: 5, 10, 20, 40, or 80 μM.

15. The method according to claim 10, characterized in that, It also includes a comparison of inflammation patterns with a lipopolysaccharide-stimulated Caco-2 cell model, detection of TNF-α and IL-6 levels in cell supernatant using enzyme-linked immunosorbent assay (ELISA), and evaluation of intestinal permeability using transmembrane resistance and FITC-D permeability assays.

16. The method according to claim 10, characterized in that, The in vivo validation steps also include: validation and inflammation pattern comparison using an IBS-D mouse model, observation of colon pathology by hematoxylin and eosin (H&E) staining, detection of TNF-α and IL-6 levels in colon tissue by ELISA, and evaluation of intestinal permeability by FITC-D permeability assay; the in vivo validation also includes detecting one or more of the following in IBS-D mouse weight, Bristol fecal score, fecal pellet number, fecal water content, and abdominal wall withdrawal reflex score.